Longitudinal monitoring for the emergence of epidermal growth factor C797S resistance mutations in non-small cell lung cancer using blood-based droplet digital PCR

Abstract

Validation of assays for the C797S mutation as a biomarker for osimertinib resistance is promising in guiding treatment decision-making for multidrug resistant non-small cell lung cancer. A newly developed droplet digital PCR (ddPCR) assay was used to retrospectively evaluate the emergence of the C797S mutation in six remnant plasma samples in this case report. It was found that the detected emergence of C797S clearly correlated with clinical signs of treatment resistance. Had these data been available to aid treatment selection in real time, there would have been hope for recaptured disease response and control instead of treatment cessation. The results of this study show that highly sensitive ddPCR methods can be used for the monitoring of emergent epidermal growth factor somatic variant mutations in circulation.

Keywords

Epidermal growth factor / non-small cell lung cancer / C797S / drug resistance

References

[1] Thress KS,Felip E,Stetson D.Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M..Nat Med2015;21:560-2 PMCID:PMC4771182

[2] Wang S,Liu C,Liu D.EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer..J Hematol Oncol2016;9:59 PMCID:PMC4957905

[3] Mellert H,Jackson L,Thurston S.Development and clinical utility of a blood-based test service for the rapid identification of actionable mutations in non-small cell lung carcinoma..J Mol Diagn2017;19:404-16

[4] Edwards V,Reese J,Pestano G.Abstract 411: Rapid and sensitive detection of EGFR C797S mutations using a blood-based droplet digital PCR assay..Cancer Res2019;

[5] Wang Z.Re-emerging C797S In Trans and Rechallenge of Osimertinib With Erlotinib..J Thorac Oncol2019;14:e81-2